Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XERS Xeris制药

已收盘 04-30 16:00:00 EDT

6.13

+0.11

+1.74%

盘后6.13

+0.00+0.06%

19:56 EDT

最高6.22	最低6.02	成交量104.62万
今开6.02	昨收6.02	日振幅3.24%
总市值10.56亿	流通市值9.74亿	总股本1.72亿
成交额642.12万	换手率0.66%	流通股本1.59亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris制药","latestPrice":6.125,"timestamp":1777579200000,"preClose":6.02,"halted":0,"volume":1046162,"hourTrading":{"tag":"盘后","latestPrice":6.1287,"preClose":6.125,"latestTime":"19:56 EDT","volume":49002,"amount":300128.2472,"timestamp":1777593416202,"change":0.0037,"changeRate":0.000604,"amplitude":0.004702},"delay":0,"changeRate":0.01744186046511635,"floatShares":159000000,"shares":172431290,"eps":0.003207,"marketStatus":"已收盘","change":0.105,"latestTime":"04-30 16:00:00 EDT","open":6.02,"high":6.215,"low":6.02,"amount":6421189.616348,"amplitude":0.032392,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.003207,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777622400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":6.02,"preHourTrading":{"tag":"盘前","latestPrice":6.03,"preClose":6.02,"latestTime":"09:29 EDT","volume":574,"amount":3500.5705700000003,"timestamp":1777555771041,"change":0.01,"changeRate":0.001661,"amplitude":0.019934},"postHourTrading":{"tag":"盘后","latestPrice":6.1287,"preClose":6.125,"latestTime":"19:56 EDT","volume":49002,"amount":300128.2472,"timestamp":1777593416202,"change":0.0037,"changeRate":0.000604,"amplitude":0.004702},"volumeRatio":1.006117,"impliedVol":0.8568,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"1131378192","title":"财报前瞻｜Xeris制药本季营收预计增38.85%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1131378192","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131378192?lang=zh_cn&edition=full","pubTime":"2026-04-30 12:52","pubTimestamp":1777524764,"startTime":"0","endTime":"0","summary":"Xeris制药将于2026年05月07日美股盘前发布最新季度业绩，市场预期收入高增、盈利修复延续。市场一致预期本季度公司收入为7,999.17万美元，同比增长38.85%；调整后每股收益为-0.01美元，同比增长90.62%；息税前利润为428.37万美元，同比增长231.43%。从已收集到的前瞻材料与市场一致预期看，看多观点占多数：共识认为本季度收入预计7,999.17万美元，同比增38.85%，EBIT为428.37万美元，同比增231.43%，调整后每股收益-0.01美元，同比改善90.62%，结构性改善仍在延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Xeris制药本季营收预计增38.85%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158086239","title":"异动解读 | Xeris制药公布创纪录业绩及乐观展望，盘前大涨7.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158086239","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158086239?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:24","pubTimestamp":1772454290,"startTime":"0","endTime":"0","summary":"Xeris制药今日盘前股价大幅上涨7.84%，引起了市场的高度关注。消息面上，Xeris制药近日披露了其2025年第四季度及全年的卓越财务表现，多项核心指标刷新历史纪录。公司通过优化运营效率与扩大市场覆盖，实现了营收与利润的双重增长。与此同时，公司还正式公布了针对2026财年的全面业绩展望，展现出对未来发展的坚定信心，预计2026年将继续保持增长势头。这一系列积极的财务数据和未来指引，显著增强了投资者对公司增长潜力的信心，从而推动了股价在盘前交易时段走强。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159119797","title":"Xeris制药公布2025年第四季度及全年创纪录业绩 并发布2026年度财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1159119797","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159119797?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:08","pubTimestamp":1772453330,"startTime":"0","endTime":"0","summary":"Xeris制药近日披露了其2025年第四季度及全年的卓越财务表现，多项核心指标刷新历史纪录。与此同时，公司还正式公布了针对2026财年的全面业绩展望，展现出对未来发展的坚定信心。\n在最新发布的业绩报告中，Xeris制药凸显了其在产品商业化与研发管线推进方面取得的突破性进展。公司通过优化运营效率与扩大市场覆盖，实现了营收与利润的双重增长，为2026年的战略布局奠定了坚实基础。\n根据最新指引，Xeris制药预计2026年将继续保持增长势头，并计划通过加速创新药物上市、拓展合作伙伴关系等举措进一步提升市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178368908","title":"财报前瞻｜Xeris制药本季度营收预计增41.71%，盈利能力拐点可期","url":"https://stock-news.laohu8.com/highlight/detail?id=1178368908","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178368908?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:59","pubTimestamp":1771815595,"startTime":"0","endTime":"0","summary":"Xeris制药将于2026年03月02日美股盘前发布最新财报，市场关注营收与盈利改善的延续性以及经营质量的验证。一致预期显示，本季度Xeris制药营收预计为8,234.00万美元，同比增长41.71%；调整后每股收益预计为0.04美元，同比增长169.48%；息税前利润预计为1,006.00万美元，同比增长405.39%。Xeris制药上季度营收为7,438.00万美元，同比增长37.06%；毛利率为85.22%；归属于母公司股东的净利润为62.10万美元，净利率为0.83%；调整后每股收益为0.00美元，同比增100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Xeris制药本季度营收预计增41.71%，盈利能力拐点可期","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110271690","title":"Xeris制药将于2026年3月2日公布2025财年全年业绩并发布2026年财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1110271690","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110271690?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:31","pubTimestamp":1771331474,"startTime":"0","endTime":"0","summary":"Xeris制药（纳斯达克代码：XERS）计划于2026年3月2日发布其2025财年全年财务报告，并同时公布对2026财年的业绩展望。该公告将详细披露公司过去一年的经营成果，并为新财年的发展路径提供明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139128234","title":"Xeris制药第三季度净利润为62.1万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139128234","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139128234?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:56","pubTimestamp":1763571385,"startTime":"0","endTime":"0","summary":"11月6日 - Xeris制药第三季度每股收益为0美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582316025","title":"Xeris制药盘中异动 急速下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582316025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582316025?lang=zh_cn&edition=full","pubTime":"2025-11-12 01:10","pubTimestamp":1762881039,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日01时10分，Xeris制药股票出现波动，股价大幅下跌5.05%。截至发稿，该股报7.33美元/股，成交量94.2084万股，换手率0.57%，振幅5.27%。Xeris制药股票所在的生物技术行业中，整体涨幅为1.29%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家美国生物制药公司，专注于开发和商业化慢性内分泌和神经疾病患者的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112011039a49a52c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112011039a49a52c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581008391","title":"Xeris制药盘中异动 早盘股价大跌14.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581008391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581008391?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:33","pubTimestamp":1762439592,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时33分，Xeris制药股票出现波动，股价快速下挫14.49%。截至发稿，该股报8.44美元/股，成交量80.0353万股，换手率0.50%，振幅6.56%。机构评级方面，在所有6家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。Xeris制药股票所在的生物技术行业中，整体涨幅为0.02%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家美国生物制药公司，专注于开发和商业化慢性内分泌和神经疾病患者的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223312a48dae2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223312a48dae2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158245930","title":"Xeris Biopharma 2025财年Q3业绩会总结及问答精华：Recorlev推动增长，XP 8121临床试验准备中","url":"https://stock-news.laohu8.com/highlight/detail?id=1158245930","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158245930?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:21","pubTimestamp":1762438891,"startTime":"0","endTime":"0","summary":"管理层强调，增长主要由Recorlev的强劲表现推动，其收入同比增长109%，患者数量增长108%。未来计划包括扩大销售团队规模以支持Recorlev的市场渗透，并为XP 8121的2026年三期临床试验做好准备。Recorlev被认为是市场中最优产品，目标是成为“十亿美元级产品”。问题5：XP 8121临床试验的时间表和研发投资趋势如何？Recorlev继续成为增长引擎，XP 8121的研发进展也为未来增长奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517437677","title":"Piper Sandler：重申Xeris Biopharma Holdings(XERS.US)评级，由中性调整至中性评级, 目标价由3.00美元调整至4.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437677","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517437677?lang=zh_cn&edition=full","pubTime":"2025-03-07 23:57","pubTimestamp":1741363032,"startTime":"0","endTime":"0","summary":"Piper Sandler：重申Xeris Biopharma Holdings(XERS.US)评级，由中性调整至中性评级, 目标价由3.00美元调整至4.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07235748604575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140090932","title":"异动解读 | Xeris制药财报亮眼 盘中股价大涨9.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140090932","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140090932?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:35","pubTimestamp":1741271712,"startTime":"0","endTime":"0","summary":"Xeris制药公司今日盘中股价大涨9.81%,主要得益于公司公布的2024年第四季度财报表现出色。\n根据公司最新的季度财报,Xeris制药实现营收6010万美元,同比大增35.39%,超出分析师预期的5810万美元。此外,公司本季度每股亏损0.03美元,较去年同期的0.10美元减少了70%,也优于分析师预期的0.06美元亏损。\n良好的财报业绩显示,公司业务发展势头强劲、盈利能力持续改善,已步入健康发展轨道。这令投资者对公司未来前景更加看好,从而推高了公司股价在今日盘中的大涨表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102660800","title":"异动解读 | Xeris制药业绩优异 盘前大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102660800","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102660800?lang=zh_cn&edition=full","pubTime":"2025-03-06 21:02","pubTimestamp":1741266152,"startTime":"0","endTime":"0","summary":"Xeris制药(XERS)今日盘前大涨5.16%,引发市场关注。具体来看:\n\n公司发布了2024年第四季度财报,亏损和营收均优于市场预期。据财报显示,Xeris制药本季度每股亏损0.03美元,远低于此前分析师预期的0.06美元亏损。与去年同期的0.10美元亏损相比,公司本季度亏损减少了70%。\n营收方面,公司本季度实现销售额6010万美元,同比增长35.39%,超出分析师预期的5810万美元。公司业绩的持续改善,令投资者对未来发展前景更添信心,从而推动股价在今日盘前大涨5.16%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198272416","title":"Xeris Biopharma Holdings 2024年第四季度GAAP每股亏损$0.03优于预期$0.06，销售额$60.10M优于预期$58.10M","url":"https://stock-news.laohu8.com/highlight/detail?id=1198272416","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198272416?lang=zh_cn&edition=full","pubTime":"2025-03-06 20:02","pubTimestamp":1741262549,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings报告季度每股亏损$0.03，优于分析师预期的$0.06，增幅为50%。相比去年同期每股亏损$0.10，本季度亏损减少了70%。以上内容来自Benzinga Earnings专栏，原文如下：Xeris Biopharma Holdings  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 50 percent. This is a 70 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $60.10 million which beat the analyst consensus estimate of $58.10 million by 3.43 percent.  This is a 35.39 percent increa","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xeris Biopharma Holdings 2024年第四季度GAAP每股亏损$0.03优于预期$0.06，销售额$60.10M优于预期$58.10M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512690321","title":"Xeris制药盘中异动 股价大涨5.15%报3.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512690321","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512690321?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:09","pubTimestamp":1739891348,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时09分，Xeris制药股票出现异动，股价大幅拉升5.15%。截至发稿，该股报3.78美元/股，成交量65.432万股，换手率0.44%，振幅5.85%。最近的财报数据显示，该股实现营业收入54.27百万美元，净利润-15.74百万美元，每股收益-0.11美元，毛利37.96百万美元，市盈率-8.76倍。Xeris制药股票所在的生物技术行业中，整体涨幅为0.69%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230908988a04b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230908988a04b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508999208","title":"Xeris制药盘中异动 下午盘股价大跌5.05%报3.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508999208?lang=zh_cn&edition=full","pubTime":"2025-02-01 03:16","pubTimestamp":1738351002,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日03时16分，Xeris制药股票出现波动，股价急速下跌5.05%。截至发稿，该股报3.48美元/股，成交量108.179万股，换手率0.73%，振幅6.28%。Xeris制药股票所在的生物技术行业中，整体涨幅为0.59%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020103164298777fb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020103164298777fb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505044432","title":"Xeris制药盘中异动 股价大涨5.00%报3.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505044432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505044432?lang=zh_cn&edition=full","pubTime":"2025-01-22 01:43","pubTimestamp":1737481404,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日01时43分，Xeris制药股票出现波动，股价大幅拉升5.00%。截至发稿，该股报3.36美元/股，成交量74.7161万股，换手率0.50%，振幅4.37%。Xeris制药股票所在的生物技术行业中，整体涨幅为2.04%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122014324abb36fc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122014324abb36fc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503588259","title":"Xeris制药盘中异动 早盘股价大跌6.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503588259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503588259?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778708,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分，Xeris制药股票出现异动，股价快速下跌6.76%。截至发稿，该股报3.17美元/股，成交量2.0161万股，换手率0.01%，振幅0.59%。Xeris制药股票所在的生物技术行业中，整体跌幅为1.01%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132231489864d5b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132231489864d5b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502098895","title":"Xeris制药盘中异动 股价大涨5.06%报3.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502098895","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502098895?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:48","pubTimestamp":1736520490,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时48分，Xeris制药股票出现波动，股价快速拉升5.06%。截至发稿，该股报3.53美元/股，成交量41.3098万股，换手率0.28%，振幅7.19%。Xeris制药股票所在的生物技术行业中，整体跌幅为0.92%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110224810aba60703&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110224810aba60703&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501844197","title":"Xeris制药盘中异动 早盘股价大跌5.08%报3.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501844197","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501844197?lang=zh_cn&edition=full","pubTime":"2025-01-08 00:26","pubTimestamp":1736267171,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日00时26分，Xeris制药股票出现异动，股价快速下跌5.08%。截至发稿，该股报3.36美元/股，成交量59.2277万股，换手率0.40%，振幅6.50%。最近的财报数据显示，该股实现营业收入54.27百万美元，净利润-15.74百万美元，每股收益-0.11美元，毛利37.96百万美元，市盈率-7.83倍。Xeris制药股票所在的生物技术行业中，整体涨幅为0.96%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010800261195fbb2d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010800261195fbb2d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493760994","title":"Xeris制药盘中异动 急速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493760994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493760994?lang=zh_cn&edition=full","pubTime":"2024-12-24 00:38","pubTimestamp":1734971890,"startTime":"0","endTime":"0","summary":"北京时间2024年12月24日00时38分，Xeris制药股票出现波动，股价急速下挫5.01%。截至发稿，该股报3.32美元/股，成交量61.5584万股，换手率0.41%，振幅4.58%。Xeris制药股票所在的生物技术行业中，整体涨幅为0.48%。Xeris制药公司简介：Xeris Biopharma Holdings Inc 是一家生物制药公司，为内分泌学，神经病学和胃肠病学的患者群体开发和商业化独特的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224003810a20542ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224003810a20542ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":0.075},{"period":"3month","weight":-0.1685},{"period":"6month","weight":-0.3794},{"period":"1year","weight":0.3651},{"period":"ytd","weight":-0.2331}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xeris Biopharma Holdings, Inc.于2005年根据特拉华州的法律成立。该公司致力于打造一家创新的、自我维持的、以增长为导向的生物制药公司，致力于通过开发一系列疗法中具有临床意义的产品并将其商业化来改善患者的生活。该公司具有独特的优势，通过三种商业产品和专有配方科学（XeriSol和XeriJect）来实现这一目标，从而建立合作伙伴关系并增强候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.070057},{"month":2,"riseRate":0.625,"avgChangeRate":-0.03111},{"month":3,"riseRate":0.5,"avgChangeRate":-0.033138},{"month":4,"riseRate":0.5,"avgChangeRate":0.031452},{"month":5,"riseRate":0.714286,"avgChangeRate":0.17169},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.067395},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009808},{"month":8,"riseRate":0.625,"avgChangeRate":0.207997},{"month":9,"riseRate":0.375,"avgChangeRate":-0.064053},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004147},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025098},{"month":12,"riseRate":0.625,"avgChangeRate":0.051713}],"exchange":"NASDAQ","name":"Xeris制药","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xeris制药,XERS,Xeris制药股票,Xeris制药股票老虎,Xeris制药股票老虎国际,Xeris制药行情,Xeris制药股票行情,Xeris制药股价,Xeris制药股市,Xeris制药股票价格,Xeris制药股票交易,Xeris制药股票购买,Xeris制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris制药(XERS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xeris制药(XERS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}